Biological Therapy in Treating Patients at High-Risk or With Lymphoma, Lymphoproliferative Disease, or Malignancies

NCT00002663 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

58

Enrollment

INDUSTRY

Sponsor class

Conditions

EBV-induced Lymphomas
EBV-associated Malignancies
Transplant Patients With EBV Viremia at High Risk of Developing a Recurrent EBV Lymphoma

Interventions

BIOLOGICAL: Epstein-Barr virus-specific cytotoxic T lymphocytes (EBV-CTLs)

Sponsor

Atara Biotherapeutics

Collaborators

[object Object]
[object Object]